Swedish specialty pharmaceutical company Pharmalink AB Stockholm has Fredrik Johansson as new Chief Financial Officer.
Gene therapy specialist Orchard Therapeutics (London) has appointed Mark Rothera as President and Chief Executive Officer, a specialist for the commercialisation of novel treatments and business development.
Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
In preparation for the development and commercialisation of Autolus’ T-cell products, the London based company announced four new senior leadership appointments.
Following Novo Nordisk, Dr. Stanislav Glezer has joined the French biopharmaceutical company Adocia as the new Chief Medical Officer. He will be responsible for designing and executing the clinical development plan of its diabetes treatments.
Swiss-based pharmaceutical company Myovant Sciences Ltd. is adding four new executives. Among them is a new Chief Medical Director, Juan Camilo Arjona Ferreira. In addition, the company increases its competence in regulatory affairs.
British pharma company GlaxoSmithKline plc. is expanding its company board and announced Laurie Glimcher as a non-executive director. Glimcher will join the board on 1 September.
German-Spanish biotech Sygnis AG has made changes to its management team and supervisory board. Heikki Lanckriet, who was previously Co-CEO, will become sole CEO of Sygnis and will also retain his role as Chief Scientific Officer.
AIM-listed Tiziana Life Sciences has a new head: The clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases appointed Kunwar Shailubhai Chief Executive Officer and Chief Scientific Officer.
Belgian biopharmaceutical company Ablynx named Markus L.E. Ewert Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the Company’s business development and corporate strategy activities and become a member of the Executive Committee.